About Tectonic therapeutic, inc.
Tectonic Therapeutic, Inc. is a biotechnology company that specializes in the discovery of antibodies and other biologic drugs targeting G-protein Coupled Receptors (GPCRs). The company was co-founded by Andrew Kruse and Tim Springer with the aim of transforming the way these drugs are discovered.
GPCRs are a family of proteins that play a crucial role in many physiological processes, including vision, taste, smell, and hormone regulation. They are also involved in numerous diseases such as cancer, diabetes, and cardiovascular disease. Despite their importance as drug targets, GPCRs have been notoriously difficult to study due to their complex structure.
Tectonic Therapeutic has developed a proprietary platform technology called Tectonic Antibody Discovery (TAD) that enables rapid and efficient discovery of high-quality antibodies against GPCRs. TAD combines cutting-edge techniques such as X-ray crystallography and phage display with advanced computational methods to identify novel binding sites on GPCRs.
The company's approach has already yielded promising results. In 2018, Tectonic Therapeutic announced a partnership with Eli Lilly to develop new therapies for autoimmune disorders using its TAD technology. Under the terms of the agreement, Eli Lilly will provide funding for research activities while retaining an option to license any resulting products.
In addition to its work on GPCRs, Tectonic Therapeutic is also exploring other areas of drug discovery such as ion channels and transporters. The company's ultimate goal is to create a pipeline of innovative biologic drugs that can address unmet medical needs across multiple therapeutic areas.
One key advantage of Tectonic Therapeutic's approach is its ability to generate highly specific antibodies against individual GPCR subtypes. This level of specificity can be critical for avoiding off-target effects that can lead to unwanted side effects or toxicity.
Another advantage is the speed at which TAD can generate new leads compared to traditional methods. By using a combination of experimental and computational techniques, Tectonic Therapeutic can rapidly screen large libraries of potential drug candidates and identify those with the highest likelihood of success.
Overall, Tectonic Therapeutic is poised to make a significant impact on the field of biologic drug discovery. With its innovative technology platform and experienced leadership team, the company is well-positioned to develop new therapies that can improve patient outcomes across a range of diseases.